Highest development stage: Phase 1

Development status: Active

Gram-negative activity

Propensity to select resistant bacteria

Mechanism of Action/Target pathogen: Carbapenem-resistant Enterobacteriaceae (CRE) and multidrug-resistant Acinetobacter; Pathogens targeted include carbapenem-resistant variants of Klebsiella pneumoniae, Acinetobacter baumanni, Escherichia coli and Pseudomonas aeruginosa.

Additional information: In Vivo Efficacy of Novel, Fully Synthetic Tetracyclines in a Murine Lung Infection Model Challenged with KPC-producing Klebsiella pneumoniae
T. Grossman, C. Fyfe, K. Kerstein, C. Sun, D. Hunt, R. Clark, X. Xiao, J. Sutcliffe